LICENSE AGREEMENTLicense Agreement • June 19th, 2020 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJune 19th, 2020 Company IndustryHMGU is a public research institution operating in the field of environmental health. Researchers at HMGU identified the endonuclease “Clo51” from the bacterial strain […***…] as an enzyme that can be used for genome editing purposes (hereinafter referred to as the “ORIGINAL MATERIAL”) as described in Annex 1. The technology involving the ORIGINAL MATERIAL is protected by the […***…].
LICENSE AGREEMENTLicense Agreement • April 17th, 2020 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledApril 17th, 2020 Company IndustryHMGU is a public research institution operating in the field of environmental health. Researchers at HMGU identified the endonuclease “Clo51” from the bacterial strain […***…] as an enzyme that can be used for genome editing purposes (hereinafter referred to as the “ORIGINAL MATERIAL”) as described in Annex 1. The technology involving the ORIGINAL MATERIAL is protected by the […***…].
LICENSE AGREEMENTLicense Agreement • December 11th, 2018 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledDecember 11th, 2018 Company IndustryHMGU is a public research institution operating in the field of environmental health. Researchers at HMGU identified the endonuclease “Clo51” from the bacterial strain […***…] as an enzyme that can be used for genome editing purposes (hereinafter referred to as the “ORIGINAL MATERIAL”) as described in Annex 1. The technology involving the ORIGINAL MATERIAL is protected by the […***…].
LICENSE AGREEMENTLicense Agreement • November 1st, 2018 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 1st, 2018 Company IndustryHMGU is a public research institution operating in the field of environmental health. Researchers at HMGU identified the endonuclease “Clo51” from the bacterial strain […***…] as an enzyme that can be used for genome editing purposes (hereinafter referred to as the “ORIGINAL MATERIAL”) as described in Annex 1. The technology involving the ORIGINAL MATERIAL is protected by the […***…].